{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:43:18Z","timestamp":1787496198480,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01468-1","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:34:05Z","timestamp":1751852045000},"page":"2483-2493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Daniel","family":"Mu\u00f1oz-Barba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Soto-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda Haselgruber-de","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"S\u00e1nchez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"3","key":"1468_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/12034754231168839","volume":"27","author":"C Sibbald","year":"2023","unstructured":"Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023;27(3):241\u201359.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1468_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"1468_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/CCID.S376096","volume":"16","author":"L Alhanshali","year":"2023","unstructured":"Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. CCID. 2023;16:803\u201320.","journal-title":"CCID"},{"key":"1468_CR4","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","volume":"14","author":"D Wei","year":"2023","unstructured":"Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol. 2023;14:1152513.","journal-title":"Front Immunol"},{"issue":"5","key":"1468_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","volume":"84","author":"V Konzett","year":"2025","unstructured":"Konzett V, Smolen JS, Nash P, et al. Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement. Ann Rheum Dis. 2025;84(5):697\u2013715.","journal-title":"Ann Rheum Dis"},{"key":"1468_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","volume":"13","author":"M Lensing","year":"2022","unstructured":"Lensing M, Jabbari A. An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13: 955035.","journal-title":"Front Immunol"},{"issue":"3","key":"1468_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1468_CR8","first-page":"13719","volume":"10","author":"M Mateos-Haro","year":"2023","unstructured":"Mateos-Haro M, Novoa-Candia M, S\u00e1nchez Vanegas G, et al. Treatments for alopecia areata: a network meta-analysis. Cochrane Database Syst Rev. 2023;10(10):13719.","journal-title":"Cochrane Database Syst Rev"},{"key":"1468_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.17641","volume":"52","author":"M Wada-Irimada","year":"2025","unstructured":"Wada-Irimada M, Takahashi T, Sekine M, et al. Predictive factors for treatment responses to baricitinib in severe alopecia areata: a retrospective, multivariate analysis of 70 cases from a single center. J Dermatol. 2025;52:701\u201311.","journal-title":"J Dermatol"},{"issue":"6","key":"1468_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40257-024-00884-x","volume":"25","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang Y. Predictors and management of inadequate response to JAK inhibitors in alopecia areata. Am J Clin Dermatol. 2024;25(6):975\u201386.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1468_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102204","volume":"32","author":"A Alshahrani","year":"2024","unstructured":"Alshahrani A, Al-Aqeel S, Alshahrani M, et al. Budget impact analysis of baricitinib for treatment of alopecia areata: a Saudi hospital perspective. Saudi Pharm J. 2024;32(12): 102204.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"1468_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/ijd.17517","volume":"4","author":"S Haselgruber","year":"2024","unstructured":"Haselgruber S, Mu\u00f1oz-Barba D, Leon-P\u00e9rez FJ, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Therapeutic burden in hidradenitis suppurativa: a cross-sectional study of 557 patients. Int J Dermatol. 2024;4(3):539\u201345.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1468_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","volume":"24","author":"DE Spratt","year":"2021","unstructured":"Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647\u201361.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1468_CR14","first-page":"397","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1468_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","volume":"41","author":"E Tan","year":"2002","unstructured":"Tan E, Tay Y, Goh C, Chin GY. The pattern and profile of alopecia areata in Singapore\u2014a study of 219 Asians. Int J Dermatology. 2002;41(11):748\u201353.","journal-title":"Int J Dermatology"},{"key":"1468_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2340\/actadv.v103.4536","volume":"103","author":"F Barati Sedeh","year":"2023","unstructured":"Barati Sedeh F, Michaelsd\u00f3ttir TE, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis. Acta Derm Venereol. 2023;103:855.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1468_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1468_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ced\/llad239","volume":"48","author":"V H\u00e9bert","year":"2023","unstructured":"H\u00e9bert V, Joly P. Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series. Clin Exp Dermatol. 2023;48(11):1258\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1468_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/jamadermatol.2022.6687","volume":"159","author":"P Joly","year":"2023","unstructured":"Joly P, Lafon A, Houivet E, et al. Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial. JAMA Dermatol. 2023;159(4):403\u201310.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1468_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1468_CR21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","volume":"14","author":"S Haselgruber","year":"2024","unstructured":"Haselgruber S, Fern\u00e1ndez-Crehuet-Serrano P, Fern\u00e1ndez-Ballesteros MD, et al. Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study. Dermatol Ther (Heidelb). 2024;14(7):1875\u201390.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1468_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14885","volume":"21","author":"D Mu\u00f1oz-Barba","year":"2024","unstructured":"Mu\u00f1oz-Barba D, S\u00e1nchez D\u00edaz M, Montero V\u00edlchez T, Molina Leyva A, Arias SS. Is there a surgical window of opportunity in hidradenitis suppurativa? Int Wound J. 2024;21(6): e14885.","journal-title":"Int Wound J"},{"issue":"2","key":"1468_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000535849","volume":"240","author":"A Borghi","year":"2024","unstructured":"Borghi A, Flacco ME, Schettini N, Toni G, Corazza M. Searching for a \u00abwindow of opportunity\u00bb in the treatment of vulvar lichen sclerosus: evidence for therapeutic benefits of an early corticosteroid treatment. Dermatology. 2024;240(2):195\u2013204.","journal-title":"Dermatology"},{"issue":"1","key":"1468_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/pharmrev.122.000612","volume":"75","author":"AHM Mustafa","year":"2023","unstructured":"Mustafa AHM, Kr\u00e4mer OH. Pharmacological modulation of the crosstalk between aberrant janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharmacol Rev. 2023;75(1):35\u201361.","journal-title":"Pharmacol Rev"},{"key":"1468_CR25","first-page":"657","volume":"20","author":"A Mourtada","year":"2025","unstructured":"Mourtada A, Douarec C, Wargny M, et al. Real-life effectiveness and safety of baricitinib in adults with alopecia areata: a multicentre study. Acad Dermatol Venereol. 2025;20:657.","journal-title":"Acad Dermatol Venereol"},{"key":"1468_CR26","first-page":"85","volume":"5","author":"IG di Corteranzo","year":"2025","unstructured":"di Corteranzo IG, Bongiovanni E, Cedirian S, et al. Safety profile of baricitinib in patients with severe alopecia areata: a prospective study. Int J Dermatol. 2025;5:85.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01468-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:12:09Z","timestamp":1757207529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01468-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01468-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel Mu\u00f1oz-Barba, Alberto Soto-Moreno, Sof\u00eda Haselgruber-de Francisco, Manuel S\u00e1nchez-D\u00edaz and Salvador Arias-Santiago have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The current study was approved by the research ethics committee of Granada (code: SICEIA-2025-000370) and was performed in accordance with the principles of the Declaration of Helsinki. All patients gave informed consent before being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}